Q-omics provides the consensus-scored MIR549A profile across patient tissues and cancer cell-line models. MIR549A expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MIR549A is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, MIR549A RNA expression shows 10,292 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ESCA, and LUAD as cancer lineages where MIR549A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR549A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR549A survival associations across molecular data types. MIR549A RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR549A RNA expression–survival associations across cancer types. High MIR549A expression shows unfavorable associations in UCEC, COAD and LUAD, but favorable associations in ESCA, SKCM and ACC. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify ESCA as the clearest survival context for MIR549A RNA expression.
This table summarizes MIR549A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR549A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR549A shows higher tumor expression in LUAD and STAD. The LUAD box plot shows higher MIR549A RNA expression in tumor versus normal tissue (log2 FC = +0.197, t-test p = .011).
This table shows molecular features associated with MIR549A in patient tissues and cancer cell lines. In patient samples, MIR549A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
